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I. Introduction
WHILE as many children grow above the 97th percen-tile (corresponding to 1 1.8 sds) as below the 3rd
percentile, tall stature is a far less common reason for seeking
medical attention than short stature. Tall stature is more
easily accepted in society and may even be an advantage.
This holds specifically true for boys, and girls are more often
referred.
Growth is a result of complex processes. Genetic consti-
tution, nutrition, endocrine function, and psychosocial well
being are all involved in the process of growth (1, 2). The
genetic component of height has been estimated to be 0.5–0.9,
i.e., 50–90% of the height variation is accounted for by genetic
factors. Assessment of the parental height as an indicator of
the genetic component of growth and development of the
child is therefore of critical importance (3). In addition, so-
cioeconomic factors such as social class, family size, birth
rank, housing, and crowding are associated with growth.
Improved socioeconomic conditions and better health have
led to the manifestation of a positive secular trend in growth
and development over the last centuries. In 1865 the mean
adult height among Dutch army recruits was 165 cm. One
century later, in 1965, the mean adult height in boys was 178
cm. Fifteen years later, in 1980, the mean adult height had
increased by another 4 cm to 182 cm. In the middle of the 19th
century, age of menarche of European girls was about 16–17
yr. Nowadays, the mean age of menarche is 13 yr or even less.
Phenomena responsible for both positive and negative
secular trends have affected height throughout our history.
Studies of fossil remains of our hominid ancestors demon-
strate that the stature of individuals living during the last
hundred-thousands of years reached the range of heights
seen today: the mean stature of early anatomically modern
Homo sapiens in Europe was 184 cm in males and 167 cm in
females (4, 5). Thus, stature is based on many factors, in-
cluding heredity and environment.
In recent years, information concerning auxology and
(neuro)endocrinology of tall stature has expanded. In addi-
tion, long-term results of height-reducing treatment modal-
ities have become available. In this review we will give an
update of the (neuro)endocrinology, the auxology, the dif-
ferential diagnosis, and the therapeutic modalities available
in the management of constitutionally tall stature (CTS).
II. Normal vs. Extremes of Growth
A. Defining CTS
A thorough understanding of the factors influencing the
process of normal growth is essential to understanding the
pathophysiology of the extremes of growth (6). It has been
well established that populations of various ethnic origin
differ considerably in growth and development. Therefore,
reference growth curves have been obtained by measuring
healthy individuals longitudinally or cross-sectionally (or
both). Extremes of growth can be defined knowing the nor-
mal variance of growth of the reference population. Usually
an individual whose height differs more than 2 sds from the
population mean, i.e., a child with a height above the 97th
percentile of the growth curve, is considered too tall just as
a child growing below the 3rd percentile is considered too
short. It should be emphasized, however, that most of the
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children who grow beyond these percentiles are part of a
continuum of a normal distribution curve, and only a mi-
nority will have a defined abnormality.
CTS is defined as a condition in which the height of an
individual is 2 sds above the corresponding mean height for
a given age, sex, and population group. As shown in Table
1, height p97 values vary substantially among various pop-
ulations. The Scandinavians and the Dutch are among the
tallest people in the world.
In CTS, usually one or both parents are tall; thus, genetic
and familial factors are most important etiologically. Mean
birth length is in the 75th percentile, and tall stature becomes
evident at the age of 3–4 yr. Growth velocity is accelerated
in early childhood but slows down after 4–5 yr of age when
the growth curve starts to parallel the normal curves (19).
The diagnosis is generally made from the family history of
growth and from physical examination. No apparent abnor-
malities are present at physical examination, which permits
distinction from excessive growth syndromes such as Marfan
syndrome and Klinefelter syndrome (see Table 2).
B. Endocrinology of CTS
A significant positive correlation has been established be-
tween growth and GH secretion in studies of children with
various heights (20–22). In a recent study, insulin-like
growth factor (IGF-I) levels in prepubertal children corre-
lated significantly with height velocity in the following year
(23). In CTS children, relatively high levels of IGF-I were
measured (24).
At the time of puberty GH secretion increases. Sex-specific
changes regarding the timing of the pubertal increase of GH
secretion during puberty have been found by analyzing 24-h
GH profiles in healthy boys and girls (25). This increase,
occurring about 1 yr earlier in girls than in boys, is correlated
to estradiol levels in both boys and girls (26, 27). Similarly,
serum levels of IGF-I rise at puberty (23). In boys with de-
layed puberty, testosterone (T) treatment caused increased
GH pulse amplitude, thereby increasing the mean serum GH
concentration. T exerts its effect on GH via an estrogen-
dependent mechanism by increasing hypothalamic GHRH
release (28). Paradoxical GH responses to glucose loading
and to administration of TRH or GHRH, similar to those seen
in acromegaly, have been observed in some CTS children
(29–31). However, these observations have not been sub-
stantiated in studies properly controlled for age and stage of
puberty. Tauber et al. (32) showed a clear heterogeneity of
GH secretion in tall children, with some of them even having
low GH secretion (32). Therefore, abnormal responses may
be related more to the stage of puberty of the child than to
abnormalities of GH secretion (33).
In conclusion, constitutionally tall children are healthy
children without hard evidence of pathology of the GH-IGF-I
axis.
III. Endocrinology of Bone Growth and Maturation
Given that stature of patients with CTS appears to have a
genetic basis, it is worthwhile to review the biological factors
known to regulate normal skeletal growth. This information
is relevant in the context of the current treatment modalities
of CTS, which are based on sex steroid action on bone growth
and maturation (see below).
TABLE 1. Mean or median and 1 1.8 SD height (p97) values (cm) in various countries
Country (year of
ascertainment)
Height (boys) Height (girls)
Reference
Mean or median (1 1.8 SD/p97) Mean or median (1 1.8 SD/p97)
The Netherlands (1985) 182.0 194.5 168.3 179.8 7
Germany (1992) 179.9 192.5 167.0 179.0 8
Sweden (1976) 179.1 192.4 165.5 178.2 9
Czechia (1993) 178.3 191.7 165.0 176.8 10
Denmark (1982) 179.4 190.4 166.0 176.0 11
United Kingdom (1995) 176.4 190.5a 163.6 176.0a 12
USA (NHCS) (1977) 176.8 187.6b 163.7 173.6b 13
France (1979) 175.0 187.0 163.0 174.5 14
Mexico (1975) 172.8 186.3 160.6 174.5 15
Turkey (1978) 173.5 186.0 160.0 171.0 16
Argentina (1987) 172.8 185.6 160.7 172.2 17
Korea (1979) 170.2 180.0 157.6 166.5 18
a p98.
b p95.
TABLE 2. The differential diagnosis of tall stature
A. Variants of normal growth: constitutionally (familial) tall
stature
B. Primary growth disorders
1. Sex-chromosome related disorders
Klinefelter syndrome and variants
XXY syndrome
XYY syndrome
2. Overgrowth syndromes with advanced bone maturation
Sotos syndrome
Weaver syndrome
Marshall-Smith syndrome
Beckwith Wiedemann syndrome
Hyperinsulinism
3. Syndromes with tall stature as outstanding feature
Marfan syndrome
Marfanoid phenotype
MEN IIB
Hemocysteinuria
Estrogen inactivity/resistance
C. Secondary growth disorders
GH excess
Precocious (pseudo) puberty
MEN IIB, Multiple endocrine neoplasia IIB.
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Longitudinal bone growth is the result of expansion of the
growth plate cartilage. As puberty proceeds, a progressive
decrease in cartilage expansion occurs. Because the vascular
invasion and resorption of calcified cartilage by chondro-
clasts exceeds cartilage expansion, there is a progressive thin-
ning of the growth plate. Ultimately, the growth plate be-
comes perforated and longitudinal bone growth ceases (34,
35).
The regulation of longitudinal bone growth is very com-
plex, and several factors, including nutritional, endocrine,
paracrine, and autocrine, are necessary (36). For normal bone
growth and maturation the gonadal steroids are essential in
conjunction with several hormones and growth factors:
1. GH. GH has been shown to stimulate long bone growth in
a dose-dependent fashion. At the cellular level GH interacts
with the GH receptor. The expression of GH receptors is
developmentally regulated in epiphyseal chondrocytes (37).
There is ample evidence that GH interacts directly with cells
of the growth plate and not only through IGF-I (vide infra).
Green and associates (38) have proposed the dual effector
theory based on in vitro observations (see also Ref. 39). This
theory states that GH is a prerequisite of cartilage matura-
tion. Priming of resting chondrocytes in the growthplate by
GH is required for IGF-I to promote ’clonal expansion’ of
growth plate chondrocytes and to stimulate skeletal growth.
More recently it has been suggested that this theory may not
apply to the in vivo situation. The presence of GH receptors
is not limited to resting chondrocytes. It was shown that both
IGF-I and GH exerted their effect at each stage of differen-
tiation rather than acting specifically upon particular sub-
populations of cells at certain phases of chondrocyte differ-
entiation (40). The observation that GH-overproducing
transgenic mice have a significantly larger size than their
controls, while IGF-I transgenic mice have a normal size,
would support the theory of a differential effect of GH and
IGF.
However, transgenic models are inadequate for studying
the independent actions of IGF-I and GH as in IGF-overpro-
ducing transgenic mice GH production is not completely
suppressed (41).
2. Thyroid hormone. Thyroid hormones are crucial for bone
growth because of their direct effects on bone. In addition,
there are indirect effects by stimulating pituitary GH release
(42), thereby increasing serum IGF-I levels. Lastly, effects of
thyroid hormone on IGF-I generation by chondrocytes have
been demonstrated (43). The obvious experiment of nature is
represented by the syndrome of resistance to thyroid hor-
mone hallmarked by short stature and marked delayed bone
maturation (44).
3. Vitamin D. In addition to the crucial role of vitamin D in
bone mineralization, several observations point to a possible
role in chondrocyte proliferation and bone growth. In rats,
proliferation of growth plate chondrocytes is decreased by
high doses and increased by low doses of 1,25-dihydroxyvi-
tamin D3 [ 1,25-(OH)2D3] (45). Moreover, short stature and
delayed bone maturation may be present in the syndrome of
vitamin D resistance (46).
4. Growth factors. As IGF-I and -II are among the most prev-
alent growth factors secreted by skeletal cells and have im-
portant actions on bone formation, it is reasonable to predict
that they play a significant role in bone growth and matu-
ration. In the circulation IGF-I and -II form a complex with
IGF-binding proteins, and there is little, if any, free IGF-I or
-II available in bone. Thus, locally secreted IGF-I and -II
acting in a paracrine or autocrine manner might play an even
more important role in the regulation of growth plate cell
function. IGFs enhance the differentiated function of the
osteoblast and increase collagen synthesis. Moreover, IGFs
decrease collagen degradation and IGF-I (but not IGF-II)
increases osteoclast recruitment (41).
The synthesis of IGF-I and -II takes place in cells of os-
teoblast lineage and is controlled by systemic hormones
(stimulatory: PTH, GH, estrogens; inhibitory: cortisol, vita-
min D) and local factors (stimulatory: bone morphogenetic
proteins, PGE2; inhibitory: fibroblast growth factor, trans-
forming growth factor, platelet derived growth factor).
In addition, skeletal cells synthesize a variety of IGF-bind-
ing proteins (IGFBP). They act to regulate and modulate the
local actions of IGFs. Most IGFBPs have been shown to have
inhibitory effects on either IGF-I or -II. However, IGFBP-5 has
been shown to potentiate IGF-II action on osteoblast- derived
cell lines (47).
IV. Sex Steroid Action on Bone
Growth and Maturation
The pubertal growth spurt has long been considered to be
an androgen-dependent process. However, there is abun-
dant clinical and experimental evidence showing that estro-
gens may be primarily responsible for accelerated growth
during puberty (48). It is remarkable that peak height ve-
locity occurs in girls and boys when estradiol levels are not
only low but also quite similar (49, 50). Still, a direct rela-
tionship between levels of E2, GH, and pubertal growth has
not been established (51, 52).
Girls with Turner syndrome show a growth spurt during
estrogen replacement therapy (53–55). Similarly, girls with
central or pseudo-precocious puberty with clearly elevated
estrogen levels show increased height velocity and prema-
ture epiphyseal closure (56). Whereas in patients with an-
drogen insensitivity syndrome the growth spurt resembled
that of women both in magnitude and timing, mean final
adult height was taller than in normal women but shorter
than in normal men (22, 48, 57). This would suggest that Y
chromosome-related factors contribute to stature. Patients
with familial male precocious puberty treated with antian-
drogens alone did not revert to a normal prepubertal growth
rate but only when an aromatase inhibitor was added (58).
Studies of acute infusion of gonadal steroids in peripu-
bertal children have illustrated the complexity of the rela-
tionship between gonadal steroids and the GH/IGF axis (49,
59, 60). These studies suggest sex differences in the control
of GH secretion in the response to E2 during puberty. More-
over, acute and chronic E2 exposure may have different ef-
fects: acute infusions decrease whereas prolonged exposure
may increase GH bioactivity (60).
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There is also evidence for a dose dependency as high doses
of estrogens result in decreased growth velocity in both
males and females (58, 61, 62). High-dose estrogen treatment
decreased IGF-I levels in acromegalic patients as well as in
tall girls (63, 64). Recently, a man was described with estro-
gen resistance. He had a normal prepubertal growth and
normal timing of onset of secondary sex characteristics. De-
spite full masculinization he continued to grow. At 18 yr his
height was 204 cm, and the growth velocity was 1 cm/yr. The
bone maturation and mineralization were both markedly
retarded (65). Moreover, a phenotypic female with aro-
matase deficiency was described showing markedly delayed
bone maturation (66). It is well known that in boys with
pseudo-precocious puberty as a result of congenital adrenal
hyperplasia, height velocity is increased and epiphyseal mat-
uration is advanced, resulting in stunted adult height. There
is ample evidence that androgen-stimulated growth is
largely based on influencing GH release and augmentation
of IGF-I. However, it is not excluded that these effects are
estrogen mediated. On the other hand, nonaromatizable an-
drogens have growth-promoting effects not mediated via
GH-IGF-I axis (67). Keenan et al. (68) reported that nonaro-
matizable DHT induced and maintained accelerated growth
rate in short boys with delayed puberty in spite of a 50%
decline in integrated GH concentration and no change of
IGF-I level, suggesting that strictly androgen-mediated skel-
etal growth might be exerted locally in growing cartilage.
In vitro studies using rat- and human-derived cells have
shown that there might be a sex-specific and age-dependent
responsiveness of cartilage and bone cells to sex steroids.
Cells and tissues derived from males respond primarily to T,
whereas cells and tissues derived from females respond pri-
marily to estrogen. The best response was obtained in tissue
from children in early puberty (69–71). The mechanism of
action of the gonadal steroids on growth plate cartilage is
poorly understood. The effect of estrogens on proliferation of
human chondrocytes in vitro was shown to be biphasic: at
low concentration a stimulatory effect was observed, while
at supraphysiological doses inhibition was observed.
High doses of estrogens stimulate the maturation of car-
tilage without increasing the growth rate: cell division by
cartilage cells is inhibited in the proliferative zone of the
growth plate, and the age-related decrease in size of the
hypertrophic chondrocytes is accentuated by estrogens (72–
76). The latter effects were not overcome by the addition of
GH or IGF, suggesting that estrogens may act directly on
chondrocytes or may influence the release of factors that
inhibit cell proliferation locally (77). Using fetal rat osteo-
blasts in culture, McCarthy et al. (78) established that estro-
gens do not alter IGF-I promotor activity but inhibit the
biological effects of all hormones that act through cAMP to
regulate skeletal IGF-I expression and activity.
Collectively, bone growth and bone maturation are the
result of a complex interplay of various hormones in which
GH and the gonadal steroids have a pivotal role. Moreover,
there might be a sex-specific and age-dependent responsive-
ness of cartilage and bone cells to sex steroids. At the level
of the growth plate, estrogen receptor-mediated processes
appear essential in expressing the effects of sex steroids.
V. Height Prediction
Height prediction plays a key role in the management of
children with growth disorders and consequently in children
with CTS. Therapeutic intervention is based on the estimated
height prognosis: whenever the height prognosis exceeds a
certain limit (usually 2 sds above the mean of the popula-
tion), treatment might be considered. Hence, accurate tech-
niques for reliable height predictions are essential. The suit-
ability and importance of skeletal maturity as a predictor
variable for adult height have long been recognized (79–82).
The techniques of Tanner-Whitehouse and Bayley-Pinneau
both share the use of bone age (BA) as an indicator of skeletal
maturity to estimate final adult height. The first prediction
method uses the BA method developed by Tanner et al. (80),
whereas the latter utilizes the BA method of Greulich and
Pyle (83). Each BA determination is linked with potential
problems as briefly summarized below (84).
A. Skeletal maturity or BA
A measure of skeletal maturity is generally obtained by
assessing the appearance and shape of the bones of the hand
and wrist on an x-ray. These appearances change with age,
and their rate of change is a direct measurement of the rate
of maturation. Various methods of evaluation of BA and
maturity have been developed over the years. The methods
most commonly used are the Greulich and Pyle Atlas (83)
and the Tanner-Whitehouse (TW2) method (79, 80). In ad-
dition, other methods such as the FELS-method are also
available (85).
The method of Greulich and Pyle for BA estimation is
presented as an atlas of examples of radiographs of the left
hand and wrist of healthy children at various ages (83). The
children who form the standard group were drawn from the
Brush Foundation Study, which selected children from the
better socioeconomic strata in Cleveland, Ohio, from 1930
onward. All the children were white, had been born in the
United States, and were of North European ancestry. Each of
the standards of the atlas was selected from a large number
of children of the same sex and age. All films were arranged
in order of increasing maturity, and the film chosen as the
standard is the one most representative of the central ten-
dency or anatomical mode. The BA is determined by com-
parison with the standards.
The Tanner-Whitehouse technique describes maturity in-
dicators for each bone of the hand and wrist (79, 80). Each
bone progresses through a series of specific stages with as-
signed weighted scores. These scores are added to form a
maturity score, which in turn can be converted to a corre-
sponding BA. The source data for this method were obtained
from large groups of British children of an average socio-
economic level in the 1950s.
The major problem in both techniques is that subjective
processes and discontinuous scales are used that result in
considerable inter- and intrarater variability in BA (84, 86–
88). In a direct comparison, the BA as determined by the
Greulich and Pyle method is generally about 1 ‘year’ less than
that as assessed by the Tanner-Whitehouse technique (86, 87,
89). One should realize, however, that BA determinations are
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estimates of maturity and that, in fact, there is no objective
quantification available. Recently, various authors have dis-
cussed the main problems of skeletal maturation assessment
and the sources of possible bias (90–92). Therefore, it is
mandatory that one is acquainted with the specific qualities
of the BA determination method used.
B. Computed assisted skeletal age-scoring systems
As stated above, estimates of BA do not advance smoothly
as the child matures but in a saltatory fashion. In the TW2
system, a difference of one stage in the rating of a particular
bone may result in an increase of 0.3 ‘years’ in BA. In actu-
ality, skeletal maturity will advance gradually. To diminish
the errors in the interpretation of maturity and to improve BA
ratings, the TW2 system has been transformed recently by the
original author into a computerized image analysis system
using a continuous scale Computer-Assisted Skeletal Age
System: CASAS (93, 94). So far, a limited number of studies
have been performed on the reliability and validity of CA-
SAS in healthy children and in children with tall stature
(95–97). Results indicate that reliability of the CASAS ratings
is extremely high, both within and across operators. More-
over, in longitudinal series, BA does advance far more
smoothly compared with manual scores. With regard to chil-
dren with tall stature, CASAS was found quite applicable.
The CASAS method, however, is not without drawbacks and
is still, to some extent, user dependent. Further develop-
ments are needed to improve these aspects.
C. Accuracy of height prediction
Prediction methods that have survived the tests of clinical
usefulness are those that incorporate a multitude of variables
relating to adult height and maturity and that are sensitive
in their assessment of childhood maturity (82). Most predic-
tion methods are based on growth data of unselected nor-
mally growing children. Therefore, when applied to children
with tall stature, critical appraisal of their qualities is re-
quired. Knowledge concerning the specific advantages and
disadvantages of the various methods is of utmost impor-
tance since it may influence possible therapeutic intervention.
Thus far, only a limited number of studies have been
performed testing the reliability of height prediction meth-
ods in large groups of untreated children with tall stature.
The accuracy of height prediction may be expressed math-
ematically as the difference between predicted adult height
and actual adult height. In this way, positive values indicate
overestimation, and negative values reflect underestimation
of the final adult height. Absolute errors demonstrate the
method’s overall predictive error and is not influenced by
over- or underestimation.
Table 3 summarizes the accuracy of various prediction
methods in boys with tall stature (98–101). The systematic
tendency of the prediction methods to over- or underesti-
mate final adult height are not consistent. Variation in initial
clinical data (CA and BA) and time definition of reaching
adult height may account for this inconsistency. In general,
however, the method of Bayley-Pinneau tends to overesti-
mate final height, whereas the method of Tanner-White-
house slightly under- or overestimates final height. Joss et al.
(102) described a systematic overprediction of the Bayley-
Pinneau technique in a study of 32 tall boys. In addition, they
reported a systematic overprediction using the Tanner-
Whitehouse method, which was even more pronounced at an
older BA. Some investigators have used repeated predictions
in the same subject for accuracy assessment. This may have
induced bias in reported means and/or standard deviations
of the errors of prediction. When the group of patients was
divided into age-specific subgroups it appeared that with
increasing age both methods became more accurate in pre-
dicting adult height (100, 101). In our study the Index of
Potential Height (IPH) based on the BA of Greulich and Pyle
was found to be the most reliable method as it showed the
lowest mean error and mean absolute error, 20.1 (2.9) cm
and 2.3 (1.8) cm, respectively (101). The IPH is based on the
assumption that the height sd scores for BA [rather than for
chronological age (CA)] remains constant up to final height.
The accuracy of height prediction methods in girls with tall
stature is given in Table 4 (64, 101, 103–109). Again, incon-
sistency is present in reported errors of prediction, probably
due to differences in initial clinical data and timing of adult
height assessment. Nevertheless, the mean errors are found
to be rather small, indicating that height prediction in tall
girls is quite accurate regardless of which method is used. As
in boys, predicting adult height became more accurate with
increasing age (101). The mean absolute errors were also
small, a confirmation of their reliability. It seems that there
is no ‘best’ prediction method in tall girls; the choice of
method for use in daily practice may therefore depend on the
preference and experience of the clinician.
TABLE 3. Mean error of prediction (cm) of the Bayley-Pinneau and Tanner-Whitehouse method in untreated constitutionally tall boys
(prediction minus actual height)
Study Number of patients
Prediction method (SD)
Reference
Bayley-Pinneau Tanner-Whitehouse
Zachmann et al. 8 12.3 10.02 (3.7) 98
Bra¨mswig et al. 9 11.7 (4.5) 11.1 (4.4) 99
Bra¨mswig et al. 42 12.1 (4.8) 10.6 (5.4) 100
Absolute error Absolute error
4.0 (3.3) 4.2 (3.3)
De Waal et al. 55 12.8 (3.6) 20.9 (4.8) 101
Absolute error Absolute error
3.3 (3.1) 3.9 (2.9)
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D. New prediction equations in constitutionally
tall children
As stated above, for children growing at the upper ex-
tremes of normal, i.e., beyond 12 sd above the mean of the
normal population, it seems far better to use prediction mod-
els based on growth data derived from a sample of tall
children. For this reason Tanner and co-workers revised their
original equations (Mark 1) (79) by including numbers of
very tall (and very short) children in the new source sample
in the standardizing group (Mark 2) (80). Unfortunately, only
tall girls had been included. This might explain the finding
of Cameron et al. (110) that the accuracy of prediction in tall
boys did not improve comparing the older TW Mark 1
method with the revised TW Mark 2 method.
To improve height prediction in children with constitu-
tionally tall stature, we developed regression equations
based on growth data derived from a sample of untreated tall
children (55 boys/88 girls) (111). Since the quality of a re-
gression model is reflected in its residual standard deviation
(RSD), the smaller the RSD the better the model predicts the
dependent variable (final height) by the combination of pre-
dictor variables. In our newly developed prediction equa-
tions the RSD was 2.5 cm for both boys and girls (see Table
5). This implies that about 95% of the predictions lie within
approximately 5 cm of the real value (6 2 RSD). From a
clinical point of view, this inaccuracy is quite acceptable. In
comparison, Tanner et al. (79) reported RSD values up to 4.1
cm in boys and 3.6 cm in girls for the same age ranges. The
prediction equations were tested on a separate sample of 32
tall children (16 boys/16 girls) and compared with other
prediction techniques including the TW Mark 2 and Bayley-
Pinneau method. The absolute errors of our prediction equa-
tions were smaller (though not reaching statistical signifi-
cance) than the TW Mark 2 method and the Bayley-Pinneau
technique, indicating less variability. These results give sup-
port to the idea that height prognosis in children with ex-
cessive growth is more accurate when based on growth data
derived from tall children.
In conclusion, although prediction techniques may have
small mean errors of prediction, it must be emphasized that
considerable errors in height prognosis may be made in
individual cases. This is reflected by the presence of the
relatively large sds of the mean errors of the prediction
method applied. It is preferable, therefore, to give predicted
adult height as a height with a confidence limit (using the
residual sds of the prediction technique for calculation).
VI. Treatment of CTS: General Concepts
Treatment of tall stature is generally based on psycholog-
ical grounds. From a strict medical point of view, there is no
reason for treatment. Therefore, the validity and necessity for
treatment are questionable. Although psychosocial factors
form the main reason for treatment, extensive psychological
investigation before or during height reductive therapy has
never been performed. Nevertheless, psychological prob-
lems in tall adolescent girls and boys have been recognized
by pediatricians and endocrinologists (112–115). A com-
monly voiced concern is that these children feel different
from their peers and that they are subject to hurtful remarks
about their height. As a consequence, coping mechanisms
such as kyphotic posture, social withdrawal, and even de-
pression have been observed. Fear about future compatible
partners (especially in girls) and career planning are also
frequently reported problems (112–115). Practical problems
for adolescents and adults alike might arise concerning cloth-
ing and shoes. Concurrent orthopedic problems, such as
kyphosis or scoliosis, could make treatment desirable for
purely mechanical reasons. A study of determinants of future
trunk abnormalities in a cohort of 11-yr-old schoolchildren
suggested that in addition to the onset of the adolescent
growth spurt and the menarche, tall stature was positively
associated with the incidence of adolescent idiopathic sco-
liosis and trunk abnormalities (116, 117).
TABLE 5. Regression equations based on samples of untreated
constitutionally tall children
Boys (n 5 71):
Final height 5 213.66 1 0.62 3 H 1 0.29 3 TH 2 10.49 3
CA 2 12.98 3 BAGP 1 0.72 3 (CA 3 BAGP);
RSD 5 2.6 cm.
Girls (n 5 103):
Final height 5 129.42 1 0.74 3 H 1 0.17 3 TH 2 7.70 3
BAGP 2 5.90 3 CA 1 041 (CA 3 BAGP);
RSD 5 2.7 cm
H, Height; TH, target height.
TABLE 4. Mean error of prediction (cm) of the Bayley-Pinneau and Tanner-Whitehouse method in untreated constitutionally tall girls
(prediction minus actual height)
Study Number of patients
Prediction method (SD)
Reference
Bayley-Pinneau Tanner-Whitehouse
Zachmann et al. 9 10.4 (3.8) 103
Reeser et al. 14 20.8 10.1 104
John and Schellong 18 11.3 (2.5) 10.7 (2.5) 105
Schambach and Nitschke 26 20.5 (2.5) 106
Bartsch et al. 23 0.6 (2.2) 107
Svan et al. 12 11.2 (1.5) 64
Ignatius et al. 28 20.9 108
21.0
10.8
Joss et al. 21 12.4 (2.9) 11.3 (2.8) 109
De Waal et al. 88 10.5 (2.7) 20.8 (3.1) 101
Absolute error Absolute error
2.0 (1.9) 2.3 (2.2)
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Sex steroids have been used in the treatment of tall boys
and girls since the late 1950s. The basis for the use of sex
hormones to limit adult height came from observations in
children with (pseudo-) precocious puberty. These children
show early closure of the epiphyses due to premature pro-
duction of gonadal steroids, which limits their eventual adult
height (118, 119).
Studies mainly in children with gonadal dysgenesis have
suggested a biphasic dose-dependent effect of estrogens on
growth rate, low dose having a stimulatory and high dose an
inhibitory effect (36, 120, 121). Furthermore, it has been dem-
onstrated that the administration of high doses of gonadal
steroids, specifically estrogens, accelerate bone maturation
(98, 99, 103, 104, 112, 122–125). Since the first study in 1956,
many reports have appeared describing the height-reducing
effect of administration of high doses of sex hormones in girls
(64, 103–109, 112, 122–131) and in boys (98, 99, 132).
VII. Treatment of Constitutionally Tall Boys
A. T treatment modalities
The effect of treatment with supraphysiological doses of T
in reducing adult height in boys appears to be different from
the effect of high doses of estrogens in girls. In T-treated tall
boys, height velocity is not decreased and even increased in
the early stages of puberty, whereas in estrogen-treated girls
a decrease in growth velocity is observed (62).
It is generally agreed that the steroid hormone effects on
bone maturation are due to an indirect action mediated by
the GH/IGF-I axis combined with a direct effect at tissue
level after metabolic conversion into estrogens (48).
The choice of the androgen preparation is unambiguous.
‘Natural’ compounds are preferred over 17-alkylated com-
pounds as it has been observed that the latter may cause
cholestasis and hepatic tumors and may negatively influence
lipoprotein levels (115). The doses of the long-acting T esters
(such as T propionate, enanthate, and decanuate) used in
most studies are about 500 mg/m2/month, which corre-
spond to roughly 4 times the normal T production rate of
adult men or to about 8–10 times that of early adolescence.
In clinical practice, two weekly im injections of 500 mg or 250
mg once a week are used. Whether such high doses are really
necessary to obtain a maximum effect on bone maturation is
not known. However, treatment with T at a mean dosage of
265 mg/m2/month resulted in a lower BA velocity and
thereby less reduction of adult height in a small group of tall
patients with hypogonadotropic hypogonadism (98). Theo-
retically, an alternative treatment modality is testosterone
undecanoate. Testosterone undecanoate in oleic acid is ad-
ministered orally and is absorbed preferentially through the
lymphatics into the bloodstream bypassing first-phase deg-
radation in the liver (133). However, dose frequency is 2–3
times a day, and circulating blood levels tend to vary sub-
stantially (134). Dose finding studies for CTS treatment have
not been performed.
B. Height reduction
The ‘uncorrected’ effect of height reductive therapy, i.e.,
height prediction minus achieved adult height, varies with
the prediction method applied. Since every single prediction
method has its own prediction error, the mean effect may be
‘corrected’ by subtraction of the corresponding mean pre-
diction errors (98, 99, 132) (see Table 6). In our own studies
the Bayley-Pinneau prediction showed the greatest mean
‘corrected’ effect of 2.0 cm, while the IPH, being the most
accurate method, calculated a mean ‘corrected’ effect of only
0.6 cm (101). An important finding, however, was that at the
time of referral the control groups (tall boys and girls) were
significantly different from children who had received sex
hormone therapy. The proper ’net’ treatment effect on final
height was calculated by multiple linear regression analysis
adjusting for differences in age, BA, and height prediction
between treated and untreated children. The mean adjusted
effect for the various prediction methods varied from 21.7
to 10.7 cm in boys. There was, however, a marked variation
in the individual height-reducing effect, ranging from 22.6
to 115.8 cm. Figure 1 shows the adjusted effect of therapy
according to the IPH-Greulich-Pyle prediction and its 95%
confidence interval.
These outcomes are clearly less than the ’corrected’ re-
ductions of 4.7–7.5 cm previously reported (98–100, 132). In
addition to the variability in adult height prediction methods
as discussed above, these conflicting results may be due to
differences in study design, comparability of the control
group, inclusion criteria (such as age and BA at start of
therapy), and therapeutic regimen. Furthermore, differences
in CA at the time of final adult height was measured, and
differences in BA at the time of cessation of therapy are
important contributing factors.
It has been clearly shown that height reduction was de-
pendent on the BA at start of therapy: height reduction was
more pronounced when treatment was started at a younger
BA (100, 101, 132). However, an important issue that caused
a significant reduction in the height-limiting effect was the
observation of a marked additional posttreatment growth
after cessation of therapy. This posttreatment growth might
partly be explained by late-pubertal completion of spinal
growth. On the other hand, the additional growth could
result from the fact that treatment had been stopped before
complete closure of the epiphyses. A significant negative
relationship between posttreatment growth and BA at the
time of stopping therapy (r 5 20.53; P , 0.001) was observed
(101). The latter contrasts with the opinion of Bra¨mswig and
co-workers (132), who advocated short-term therapy and
reported significant height reduction (uncorrected: 7.6 cm)
with a mean BA (sd) of 15.3(0.8) yr at the time of stopping
therapy. However, these results seem too optimistic, since
final height assessment was performed at a relatively young
mean (bone) age. Moreover, others failed to show any height
reducing effect using the same therapeutic strategy, but with
assessment of final height at a definite later point in time
(135).
As illustrated in Fig. 1, when therapy was started at a BA
of 14 yr or older, adult final height significantly exceeded
height prognosis at the time of start of treatment. This sug-
gests that treatment had resulted in induction rather than
reduction of growth.
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C. Effects on gonadal function
High doses of T induce suppression of the hypothalamo-
pituitary-gonadal axis (113, 136). Contraceptive studies in
adult men have shown that androgen-induced suppression
of gonadotropins and of spermatogenesis is reversible (137,
138). However, extrapolation of these data to the manage-
ment of tall stature in pubertal boys must be viewed with
caution since factors that regulate spermatogenesis in nor-
mally functioning adult testes may not be the same as during
puberty (139). Androgen therapy in tall boys is usually ini-
tiated at the first signs of puberty, and it is in this peripubertal
period that important maturational changes take place in the
testis (139–144). Influenced by complex hormonal actions,
these maturational processes eventually lead to initiation of
spermatogenesis. Onset of spermatogenesis (spermarche) as
detected by urine analysis (spermuria) appears to be an early
pubertal event: the median age of spermarche has been es-
timated to be 13–14 yr (145–148). In addition, it is noteworthy
that administration of T esters at high doses may cause mor-
phological and cytological changes, as shown in rat and
human adult testes (149–151).
1. Plasma hormone levels. High T levels are obtained during
treatment with supraphysiological doses of androgens sup-
pressing the hypothalamo-pituitary-gonadal axis (152).
Zachmann, Prader, and co-workers (98, 113) reported a
slow recovery of pituitary gonadotropins during LHRH-
stimulation tests after discontinuation of T therapy. Bra¨m-
swig et al. (136) demonstrated normalization of gonadotropin
levels in 100 tall boys after discontinuation of treatment with
follow-up periods up to 48 months, although transient hy-
pergonadotropic LH- and FSH- secretory patterns were ob-
served. In a recently published study by the same group
(153), hormonal levels and testicular function were evaluated
after a follow-up period of approximately 10 yr and com-
pared with normal volunteers. Mean values of LH, FSH, PRL,
T, estradiol, and sex hormone-binding globulin were in the
normal range in both groups. T was lower and FSH was
higher in treated tall men compared with volunteers, but the
only statistically significant difference was for T. We ob-
served different levels of gonadotropins in previously
treated tall men compared with controls (tall and ‘normal’
men) (154). Androgen-treated tall men had significantly
higher FSH levels compared with controls. Levels of plasma
hormones were not significantly correlated with parameters
of sperm quality; however, we observed significant negative
correlations between plasma FSH levels and sperm concen-
tration as well as the age at start of therapy in the androgen-
treated men. We speculate that the higher levels of FSH may
reflect intratesticular changes due to androgen treatment
received during a period of testicular maturation especially
during the earlier pubertal stages (155). These increased FSH
levels may compensate for partially disturbed germinal func-
tion to maintain normal sperm quality (156). In a subgroup
of previously treated and untreated men, we also measured
inhibin B, which probably is a more direct marker of sper-
matogenesis than FSH (157). We found similar levels, well
within the normal range (F. H. De Jong and W. J. De Waal,
unpublished results). On the other hand, the difference inTA
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gonadotropin levels may also reflect a change in responsive-
ness at the hypothalamo-pituitary level (136).
2. Testicular volume. Treatment with high doses of androgens
induces reduction in testicular volume in adult men (158) as
well as in tall adolescent boys (98, 99, 113). This implies major
intratesticular changes during therapy such as a decrease in
seminiferous tubule size (149, 150). These processes are likely
to be reversible since testicular volume normalizes after dis-
continuation of therapy as shown in several studies (98, 99,
113, 158). This is in contrast to the observations of Willig et
al. (159, 160), who reported significantly smaller testicular
sizes in previously treated men. In contrast, in our studies at
a mean follow-up period of 8 yr after cessation of treatment,
there was no difference in mean testicular volume between
treated and untreated tall men (154).
3. Sperm quality. When sperm quality is evaluated, one must
be aware of the normal distribution in the population as well
as of confounding factors interfering with parameters of
sperm quality. It is well established that varicocele (161–164),
smoking (165), sexually transmitted disease (166), and cryp-
torchidism (167) are likely to affect sperm quality and/or
plasma hormone levels. Semen analysis in our study of pre-
viously androgen-treated men showed that sperm quality
was comparable with a control group of untreated tall men,
even after correction for the above mentioned possible in-
terfering conditions, after a mean follow-up period of 8 yr.
These findings are in agreement with the experiences re-
ported by Zachmann and Prader and co-workers (98, 113). In
contrast, Willig and co-workers (159, 160) found significantly
reduced sperm concentrations in previously treated tall men
compared with controls. Their control group, however,
showed a relative high mean value of sperm concentration
of 120.2 3 1096/ml, almost twice as high as values found in
the normal population at present (168, 169). Their treated
group showed a mean sperm concentration of 63.4 3 1096/
ml, which is comparable with values found in our study
(154). It is possible that differences in patient selection, semen
analysis methodology, and treatment regimens may account
for the observed differences. In addition, the extent to which
interfering conditions are present may cause important bias
as well. In a recent report Lemcke and co-workers (153)
showed that 10 yr after T treatment, none of the tall men had
azoospermia, and the mean ejaculate parameters were in the
normal range or only slightly subnormal. Overall, seminal
parameters of T-treated tall men were slightly, but not sig-
nificantly, lower compared with normal statured volunteers.
Interestingly, they found a significantly higher prevalence of
varicocele and maldescended testes in the tall men compared
with their control group of normal volunteers (153). They
surmised that varicocele and maldescended testes, rather
than T treatment, caused the somewhat lower semen quality
in the tall men. In our studies in treated and untreated tall
men, we observed an overall prevalence of varicocele of 42%
(12% subclinical and 30% clinical) (154). This would suggest
that varicocele occurs more often than reported in the normal
population (12.4–25.8%) (170–172). A relationship to andro-
gen treatment is unlikely since no difference in the preva-
lence of varicocele was observed between androgen-treated
men and controls. One could speculate on the impact of
stature on the pathogenesis of varicocele (153, 154).
4. Pregnancy/paternity. Thus far, only casuistic and exclusive
female data have been available on successful pregnancies
after height-reductive therapy. At the time of our follow-up
studies five of the 43 androgen-treated men and six of the 30
untreated tall men had fathered one or more children (154).
All 11 men reported that pregnancy had occurred in their
partners after less than 1 yr of unprotected coitus. Two other
pregnancies, fathered by a previously treated man and a
control, respectively, ended in spontaneous abortion. These
very limited numbers do not allow any further conclusions.
FIG. 1. Adjusted effect of androgen therapy. The effect of therapy was calculated by multiple regression analysis using final height as dependent
variable and treatment, and CA, BA, and height prediction (and their interactions) as independent variables. Using the height prediction
according to the index of potential height for bone age, the estimated treatment effect was a linear function related to BA (Greulich and Pyle)
in the form: Effect (cm) 5 44.19–3.15 3 BA (yr). The solid dots (F) represent all patients with a given bone age, and the open triangles ()
represent the 95% confidence interval of the calculated adjusted effect. [Reproduced with permission from W. J. de Waal et al.: J Clin Endocrinol
Metab 81:1206–1216, 1996 (101). © The Endocrine Society.]
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D. Other clinical effects
Many patients experience side effects during therapy (98,
99, 113, 132, 173, 174). Most of these, however, are mild and
transient (see Table 7). In some patients, slight to moderate
edema, notably in the pretibial or malleolar area, was asso-
ciated with marked weight gain during the first 6 months of
treatment. This indicates that the early gain in weight is not
only due to protein anabolism but also to water retention
(98). Acne was by far the most reported side effect (98, 99,
175). Occasionally acne fulminans has been reported and
necessitated discontinuation of therapy (173, 176). A causal
relationship with androgen therapy is likely as shown by
Fyrand et al. (177). Hinkel et al. (178) investigated the effects
of high doses of androgens on lipoproteins during and after
the cessation of therapy. Although during treatment a sig-
nificant fall of triglycerides and HDL was observed, all val-
ues normalized after the end of treatment (178). In our stud-
ies, gynecomastia occurred in 13% of the cases. Since
gynecomastia is rather prevalent in population studies in
pubertal boys (179), it is difficult to say whether the condition
had increased. One would expect that treatment would have
effects on sexuality (sex interest, masturbation). Although in
one study a marked increase of sexuality in younger, but not
in older patients, was noted, it never exceeded the normal
range seen in adolescence (98). Treatment with supraphysi-
ological doses of T were not shown to provoke aggressive
behavior in adolescents or young adults (180, 181).
VIII. Estrogen Treatment in Tall Girls
A. Estrogen treatment modalities
In 1956 Goldzieher introduced estrogen as a treatment of
excessive growth in adolescent girls (182). Since then, many
reports have appeared describing the height-reducing effect
of high-dose estrogen therapy in tall girls (64, 101, 103–109,
112, 122–131). Many investigators, mainly in the United
States, treated excessively tall girls with conjugated estro-
gens (114). In Western Europe, others used ethinyl estradiol
(EE) in varying dosages usually combined with a progesto-
gen 7–10 days each month to induce cyclic bleeding and to
avoid overstimulation of the endometrium (103, 107, 131).
Norethisterone, medroxyprogesterone, and dydrogesterone
have been used as progestagen, 5–10 mg/day. The two last
preparations, in particular, show low to absent androgenic
effects (183). In the past, estrogens have been administered
in the form of stilbestrol, 1–5 mg per day (112, 113, 182, 184).
However, since it has been reported to cause vaginal cancer
in the female offspring of women treated during pregnancy
(185, 186), stilbestrol is not a suitable treatment modality. It
has the additional disadvantage of inducing marked pig-
mentation and hyperkeratosis of the nipple. Estradiol esters,
such as estradiol-valerate and -benzoate, have been used
since they were considered to be more ‘physiological’ than
oral ethinyl estradiol (EE) or conjugated estrogens (113, 187).
A disadvantage is that three injections per cycle are required.
Considering all advantages and disadvantages, it appears
that EE is the preparation of choice, since the dose is stan-
dardized, administration is easy, and side effects are not
more marked or frequent than with any other preparation
(103). Whether the estrogens are given continuously or cy-
clically seems to be of minor importance for the effect on
height or for the resumption of regular menstrual cycles after
discontinuation of treatment (103). It seems that the pitu-
itary-gonadal axis tolerates continuous therapy for a period
of 1–2 yr very well. In the 1960s most practitioners used 500
mg EE; in the 1970s 200–300 mg were used, and in the 1980–
1990s a dosage of 100 mg/day was claimed to be sufficient
(101, 106, 107, 109, 113, 114, 125, 130, 131, 183, 188–191).
Whether even lower dosages (e.g., 35 mg daily) are equally
effective remains to be assessed in a prospective clinical trial
(131).
B. Height reduction
Studies on the effect of height reduction in tall girls have
shown various results using different prediction models
within the same study population (104, 105, 107–109, 124,
127, 129). The mean calculated effect of therapy is ‘corrected’
by subtracting the systematic prediction error, as has been
commonly reported in the literature. The mean reported
height reduction (‘corrected’ and uncorrected) in girls with
CTS ranged from 2.1 to 10 cm (64, 101, 103–109, 112, 122–131)
(see Table 8). A clear comparison, however, is hampered by
differences in initial clinical data (especially CA and BA),
duration of treatment, therapeutic regimen (different doses
and estrogen preparations), and the point in time of final
height assessment. Concerning the latter, De Waal et al. (101)
observed a mean (sd) additional growth of 2.7 (1.1) cm after
cessation of therapy, which is of the same order of magnitude
as in boys (107, 123, 127). The cause of the observed addi-
tional growth is not quite clear. It could be explained by
cessation of therapy before complete closure of the epiphy-
ses. In addition, it is plausible that part of the remaining
posttreatment growth reflects additional spinal growth.
As discussed earlier, evaluating the effect of sex steroid
treatment after ‘correction’ for the mean errors of the sepa-
rate prediction methods might induce bias. To calculate the
‘net’ treatment effect, multiple regression analysis has been
used while adjusting for differences in age, BA, and height
prediction between treated and untreated children. The
mean adjusted effect for the various prediction methods var-
ied from 1.1 to 2.4 cm and ranged from 22.6 to 6.2 cm in girls
(101). These mean results are less than previously claimed
TABLE 7. Reported percentages of side effects during hormonal
therapy in boys with CTS
Side effect
Reported percentage in study
Bra¨mswig
et al. (99)
De Waal et al.
(101)
Binder
et al. (181)
Aggravation of acne 64 39 28
Painfulness of injection 8 16
Weight gain 14
Gynecomastia 13
Muscle ache 13
Edema 9
Change in psychological/sexual
behavior
0 5 7
Hypertrichosis 13
Decreased performance after
treatment
20
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TABLE 8. Effect of hormonal treatment in girls with CTS
Study (Ref.) n Therapy CA G-P BA B-P Pred HT,uncorrected
Final HT
correcteda TW BA
TW Pred HT,
uncorrected
Final HT
correcteda
Zachmann et al. (1975) (103) 40 EE, 0.3 mg/day 12.9 (1.2) 13.4 (0.5) 4.6 (2.4) 4.2
9 Controls 14.1 (0.9) NR 0.4 (2)
Wettenhall et al. (1975) (112) 87 Stilbestrol 3 mg/day 13.0 (1.1) 13.2 (0.8) 3.5 (2.2)
Von Puttkamer et al. (1977)
(122)
41 Conjugated estrogens,
7.5 mg/day
13.0 (1.4) 12.4 (0.8) 7.3 (2.0)
Kuhn et al. (1977) (123) 17 EE, 0.5 mg/day 12.7 (1.2) 12.6 (0.6) 6.2 (2.8)
Reeser et al. (1979) (104) 14 EE, 0.2 mg/day 10.6 (0.4) 10.4 (0.5) 9.3 (1.1) 10.2 NR 7.1 (1.4) 7.0
14 Controls 10.7 (0.3) 11.2 (0.4) 20.8 (0.8) NR 0.1 (2)
John and Schellong (1980) (105) 71 EE, 0.3 mg/day 12.5 (1.1) 12.7 (0.8) 5.2 (2.8) 3.9 13.3 (0.8) 5.7 (2.9) 5.0
18 Controls 12.3 (1.3) 12.5 (1.3) 1.3 (2.5) 13.4 (1.3) 0.7 (2.5)
Andersen et al. (1980) (127) 40 Estradiovalerate, 30 mg
month im
12.6 (1.4) 11.8 (1.0) 5.0 (3.7) NR 2.9 (3.4)
Sto¨ver and Kollmann (1982)
(128)
46 Conjugated estrogens,
7.5 mg/day
12.7 (1.2) NR 5.8 (3.2) 13.0 (0.6) 4.1 (2.4)
Sorgo et al. (1984) (129) 14 EE, 0.3 mg/day or
conjugated estrogens,
7.5 mg/day
12.0 (1.4) 11.8 (1.4) 6.5 (5.5) 4.2 12.7 (1.0) 5.5 (5.5) 2.1
7 Controls 13.5 (1.5) 13.1 (1.1) 2.3 (3.6) 13.6 (1.1) 3.4 (3.7)
Schambach and Nitschke (1985)
(106)
20 Mestrenol 33/month
80 mg/day
9.8 (0.7) 9.3 (0.4) 7.6 (1.7) 8.1
20 Idem 10.1 (1.0) 10.4 (0.4) 5.5 (2.0)
16 Idem 11.7 (0.9) 11.5 (0.4) 3.0 (1.3)
30 Idem 12.3 (0.9) 12.6 (0.4) 2.2 (0.6)
26 Controls 9.2 (0.7) 9.4 (0.4) 20.5 (2.5)
Bartsch et al. (1988) (107) 35 EE, 0.1 mg/day 12.3 (2) 12.5 (2) 4.2 (2.3) 3.9 13.1 (2) 4.0 (2) 3.6
23 Controls 12.5 (2) 12.5 (2) 0.6 (2.2) NR 0.4 (2)
Gru¨ters et al. (1989) (130) 38 EE, 0.5–0.3 mg/day 12.5 (1.6) 12.4 (0.8) 4.9 (2.6)
44 EE, 0.1 mg/day 12.4 (1.4) 12.4 (0.8) 5.1 (2.4)
Svan et al. (1991) (64) 21 EE, 1.0 mg/day 13.4 (1.5) 12.9 (0.8) 5.5 (2.7) 4.3
20 EE, 0.5 mg/day 13.3 (1.0) 12.8 (0.7) 5.9 (3.3) 4.7
15 EE, 0.25 mg/day 13.5 (1.1) 12.6 (0.9) 5.6 (2.7) 4.4
12 Controls NR NR 1.2 (2)
Normann et al. (1991) (131) 263 EE, 0.5 mg/day 13.2 (2) 12.6 (2) 5.9 (2)
178 EE, 0.25 mg/day 13.1 (2) 12.6 (2) 5.3 (2)
98 EE, 0.1 mg/day 13.8 (2) 12.7 (2) 4.4 (2)
Joss et al. (1994) (109) 16 EE, 0.5 mg/day 12.8 (0.9) NR 6.9 (1.6) 4.5 12.5 (0.3) 5.1 (2.7) 3.8
25 EE, 0.3 mg/day 12.8 (0.9) NR 6.6 (2.4) 4.2 12.5 (0.4) 4.3 (2.4) 3.0
11 EE, 0.1 mg/day 13.5 (0.9) NR 6.5 (2.1) 4.1 12.5 (0.3) 3.6 (2.1) 2.6
21 Controls 13.0 (1.1) NR 2.4 (2) 12.6 (1.1) 1.3 (2.8)
De Waal et al. (1996) (101) 159 EE, 0.2 mg/day 12.7 (1.2) 12.4 (1.0) 4.1 (3.0) 3.6 13.3 (1.1) 1.4 (3.3) 2.2
88 Controls 12.8 (1.5) 12.9 (1.4) 0.5 (2.7) 13.8 (1.3) 20.8 (3.1)
Binder et al. (1997) (181) 56 Conjugated estrogens
7.5 mg/day
12.9 (1.2) 12.5 (0.6)b 3.7 (3.6) 3.6
79 Controls 11.8 (1.5) 12.3 (1.4) 0.1 (3.6)
Data are expressed in centimeters as mean (SD). N, number; CA, chronological age at start of treatment; BA, bone age at start of treatment; EE, ethinyl estradiol; BP,
Bayley-Pinneau (ref); TW1, Tanner-Whitehouse Mark 1 (80); TW2, Tanner-Whitehouse Mark 2 (80); TW-RUS, bone age RUS score according to method of Tanner-Whitehouse (80);
BA-GP, bone age according to method of Greulich and Pyle (83); NR, not reported.
a Correction by subtraction of the mean prediction error of the control group.
b Bone age at start of study; bone age at start of treatment not given.
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(64, 103–109, 112, 122–131), probably due to differences in
statistical approach and study design, as explained above.
Various studies show (as illustrated in Fig. 2) that the effect
of treatment was more pronounced when treatment had been
started at a younger BA (105, 108, 112, 123, 130, 131). How-
ever, others did not find such a relationship (103).
Results are inconsistent concerning whether or not pre-
menarcheal girls may experience more height reduction
compared with postmenarcheal girls. Some reports are in
favor of this finding (109, 122, 123, 125) while others observed
no difference (103, 107, 128, 130). In our study (101), pre-
menarcheal girls seem to benefit more from therapy than
postmenarcheal girls. However, this was likely to be due to
the differences in CA between the groups since we found no
additional effect of menarche on CA explaining the variabil-
ity in the effect of treatment. This may, at least in part, explain
the conflicting results.
C. Effects on gonadal function
1. The hypothalamo-pituitary-gonadal axis and menstrual cycles.
Suppression of the hypothalamo-pituitary-gonadal axis in-
duced by pharmacological doses of estrogens via a negative
feedback mechanism was found to be reversible (136, 192).
Hanker et al. (192) assessed the functional state of the hy-
pothalamo-pituitary axis by standardized LHRH testing in
16 tall girls treated with 300 mg EE daily for 7–26 months.
While absent LH responses were observed in all girls im-
mediately after therapy was stopped, 4 to 8 weeks later the
LH responses had normalized in 13 girls and 12 weeks after
therapy in 14 girls. All girls experienced spontaneous men-
strual bleeding within 3 to 22 weeks after termination of
therapy. The same was observed in most later follow-up
studies in which first menstruation was reported within 1–6
months after cessation of treatment, in most cases even after
the first month (103, 114, 127, 130). Amenorrhea of longer
than 6 months after cessation of height-reductive therapy
was reported in about 5% of the cases (175). The incidence of
prolonged amenorrhea after cessation of oral anticonceptive
therapy is about 0.5% (193). In addition, the overall preva-
lence of secondary amenorrhea of more than 6 months in
women aged 15–34 yr is about 1.3% (194). This may suggest
an increase of amenorrhea after height-reductive therapy. It
should be noted, however, that there are no convincing data
that use of oral contraceptives (OCs) is causally related to
amenorrhea and that other risk factors for amenorrhea, such
as smoking, nutrition, and exercise, were not adequately
investigated (193, 195). No differences were found in men-
strual cycle characteristics between previously treated and
untreated tall women after a mean follow-up period of al-
most 11 yr (175).
2. Pregnancy. In girls, pregnancy, which is the ultimate ’proof’
of complete reversibility of hypothalamo-gonadal suppres-
sion, has been reported in various single cases (112, 113, 127,
128, 130, 131, 189). In our own study, information on a total
of 63 pregnancies was obtained from 40 previously treated
tall women. No distinct differences in details and outcome of
pregnancies between treated and untreated tall women were
found (175). These results indicate that long-term effects of
high doses of estrogens on fertility are unlikely.
Although a mean follow-up period of 10 yr is still too short
to draw definite conclusions, there is no clear evidence that
treatment with high doses of sex steroids does induce harm-
ful effects on reproductive function in tall girls.
D. Other adverse effects
In most studies, unwanted side effects have been reported
only during treatment or shortly after discontinuation of
therapy (109, 112, 113, 127, 128, 130, 131, 183, 189, 196, 197).
Most side effects were found to be mild and reversible (see
Table 9). In a large retrospective study short-term and long-
term effects of high doses of estrogens in the management of
CTS were evaluated at a mean follow-up period of 10 yr after
discontinuation of height-reductive therapy. OCs were used
by a high proportion of previously estrogen-treated girls as
well as controls. An impressive bulk of data on the associ-
ation between long-term OC use and possible health risks
(reviewed in Refs. 198 and 199) form an excellent reflection
of the prospective risk in estrogen-treated girls. The propor-
tion of OC’s use and reported side effects were not signifi-
cantly different between estrogen-treated and nontreated
women. More than 70% of the estrogen-treated women had
experienced one or more side effects during therapy, such as
weight gain, headache, nausea, leg cramps at night, in-
FIG. 2. Adjusted effect of estrogen ther-
apy. The effect of therapy was calcu-
lated by multiple regression analysis
using final height as dependent vari-
able and treatment, and CA, BA, height
prediction, and menarche (0 2 no; 1 2
yes) (and their interactions) as indepen-
dent variables. Using the Bayley-Pin-
neau prediction method, the estimated
treatment effect was a linear function
related to BA (Greulich and Pyle) in the
form: effect (cm 5 20.22 3 1.44 3 BA
(yr.). The solid dots (F) represent all
patients with a given bone age and the
open triangles () represent the 95%
confidence interval of the calculated ad-
justed effect. [Reproduced with permis-
sion from W. J. de Waal et al.: J Clin
Endocrinol Metab 81:1206–1216, 1996
(101). © The Endocrine Society.]
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creased pigmentation of areola and nipples, and vaginal
discharge. Although most of them were mild and transient,
the adverse effects of estrogens occurred more frequently
during therapy than during OC use (175). This would sug-
gest a dose-dependent effect of estrogens on the incidence of
adverse events (107, 130).
Although hemostatic changes have been reported (196,
200, 201), thrombosis is found to be a very uncommon side
effect of height-reductive therapy (112, 132, 196). Whenever
thrombosis occurred it usually coincided with other risk
factors for thromboembolism such as immobilization (202).
Galactorrhea is an infrequent side effect of estrogen therapy
in tall girls (113, 123, 183). Hyperprolactinemia may be more
frequent but is reversible in most cases (Ref. 192 and M. C.
A. M. Houdijk and H. A. Delemarre-Van de Waal, submitted
for publication).
The effect of high-dose estrogens on lipid metabolism was
evaluated in several studies (178, 204). The changes of serum
lipids and lipoproteins during estrogen therapy were revers-
ible after cessation of treatment.
Malignancy was not reported in our follow-up study (175).
Although there have been no reported cases of ovarian, uter-
ine, vaginal, or breast malignancies in girls treated for tall
stature, the risk of cancer in young women receiving estro-
gens remains uncertain. The possibility of a dose-dependent
effect and a relationship with OC use at a young age and
duration of OC use with increased risks of breast cancer (205)
point to the need for long-term follow-up of patients treated
with pharmacological doses of estrogens.
IX. Alternative Treatment Modalities and
Future Research
An alternative strategy to limit growth in children with tall
stature utilizes interference in the regulation of GH secretion.
It is based on the assumption that tall stature is related to GH
hypersecretion. Bromocriptine therapy has been proposed as
a means to suppress endogenous GH secretion. Bromocrip-
tine is a dopamine agonist and inhibits GH secretion in
patients with acromegaly by binding to pituitary dopamine
receptors (206). In the 1980s, studies on the effectiveness of
bromocriptine in reducing final adult height in children with
CTS revealed conflicting results. The studies of Evain-Brion
and colleagues (207–210) reported marked decreases in
height prediction in a group of about 30 adolescents after a
treatment period of 9–15 months. It was stated that the re-
ductive effect on height prediction was mainly due to an
increase in bone maturation rather than a decrease in height
velocity; IGF-I and IGF-II levels remained unchanged. In
contrast, other studies did not substantiate the effect of bro-
mocriptine treatment on height prediction or skeletal mat-
uration in children with tall stature (211–213). Recently, re-
search has focused on somatostatin analogs for the
management of tall stature. Somatostatin is a neurohormone
produced at the hypothalamic level that has potent inhibi-
tory properties on GH release in the pituitary via the vascular
network of the portal system (214). Preliminary data revealed
an effective suppression of GH secretion in small groups of
tall children and a significant reduction in growth rate and
predicted adult height (215–218). In addition, plasma IGF-I
levels decreased whereas bone maturation accelerated in
many of the treated children (216). The effect of somatostatin
on bone maturation suggests that somatostatin acts not only
by systemic hormonal effects on GH and/or IGFs but also by
local regulatory effects on bone growth and metabolism. This
hypothesis is supported by the observation of Lamberts
(219), who found symmetrical bands of increased radioac-
tivity by means of in vivo somatostatin receptor-imaging
techniques at the epiphyseal surfaces of children with neu-
roblastoma. Final results on height reduction by somatosta-
tin therapy have not yet been established, and the possibility
of serious side effects such as gall stones must be considered.
Strategies to limit final height of tall children have centered
around the peripubertal years. This is mainly due to the use
of high doses of sex steroids to advance skeletal maturation.
Hindmarsh et al. (218) suggested that in the management of
children with tall stature, attempts should be made to reduce
the prepubertal contribution to stature. Since prepubertal
growth is largely GH dependent, somatostatin analogs might
be used to reduce the actual height from which the pubertal
growth spurt will commence. In addition, sex steroid therapy
may be applied as an adjuvant during puberty to optimize
the ultimate height-reducing effect. Other possibilities are
low-dose sex steroid treatment starting at an early prepu-
bertal age (106), or orthopedic modalities such as bilateral
epiphysiodesis around the knee (220) or femoral shortening
(221).
X. Conclusions and Recommendations
Treatment of CTS is generally based on psychological
grounds. Children and adults with excessive growth may
suffer considerably from being much taller than their peers.
Although psychosocial factors form the main reason for
TABLE 9. Reported percentages of side effects during hormonal
therapy in girls with CTS
Side effect
Reported percentage in study
John and
Schellong (105)
Trygstad
(183)
De Waal
et al. (101)
Binder
et al. (181)
Headache/migraine 14 2 13
Nausea/vomitus 27 66 14
Fluor vaginalis 10 2 13
Pigmentation of are-
ola and nipples
38 23 27
Weight gain 44 90 41 13
Calf cramp ,1 20 17
Change in psycho-
logical/sexual be-
havior
,1 3
Galactorrhea 2 4
Hypertrichosis ,1 3
Thrombosis —
Hypertension 2
Bleeding distur-
bances
11 2 9
Cysts or tumors in
mammae/uterus
or ovariae
,1 2
Polyphagia ,1 4
Striae 44 3
Dizziness/orthostatic
problems
1 7
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treatment, extensive psychological investigation before or
during height-reductive therapy has never been performed.
There are no objective prospective data indicating lifelong
psychosocial damage as a result of tallness. In two retro-
spective studies men and women previously treated with
high doses of sex steroids because of CTS showed no major
psychological maladjustment compared with tall controls
(180, 181). Nevertheless, many tall individuals experience
practical problems concerning clothing and shoes, are teased,
and are subject to hurtful remarks and jokes about their
height. Thus, careful attention should be paid to the psy-
chosocial problems related to tallness especially in relation to
the sociocultural environment when considering treatment.
Prospective controlled studies that answer the main ques-
tion of whether treatment with pharmacological doses of sex
steroids is effective in reducing final height have never been
performed. As claimed effectiveness is based on height pre-
diction, a critical appraisal of the quality of the various pre-
diction methods is in order. Height prediction in tall girls is
more accurate than in boys.
It is suggested that height prognosis in children with ex-
cessive growth is more accurate when based on growth data
derived from untreated tall children (101). It must be em-
phasized that although prediction techniques may have
small mean errors of prediction, in individual cases consid-
erable errors in height prognosis may be made. This is re-
flected by the presence of the relatively large sds of the mean
errors of the prediction method applied (191). It is preferable,
therefore, to give predicted adult height as a height with a
confidence limit using the residual sds of the prediction
technique for calculation (see Table 5). Repeated measure-
ments at intervals of 4–6 months will improve the clinical
relevance of the prediction. Treatment with supraphysiologi-
cal doses of sex steroids has been advocated for final height
reduction since 1950.
When the many reports in the literature on the height-
limiting effect of sex steroid treatment are analyzed, one may
conclude that height reduction is dependent on the BA at the
time of start of treatment. In our experience, tall girls benefit
more from sex steroid therapy than tall boys, but data from
the literature are not consistent.
As shown in Figs. 1 and 2, the period during which ef-
fective height reduction is to be expected is quite limited. The
upper limit of this period is determined by BA (Greulich and
Pyle) of ,14 yr in boys and of ,13.5–14 yr in girls. The lower
limit is determined by psychosocial constraints, as treatment
clearly induces puberty. Posttreatment growth caused by
cessation of treatment before complete closure of the epiph-
yses may cause a significant reduction of the height-limiting
effect of treatment. The optimal dose of sex steroids is not
known. In the course of time the dosage of oral ethinyl
estradiol for girls has been reduced gradually from 500 mg/
day to 100–200 mg/day. In boys, long-acting T esters, 1000
mg/m2/month, is most often recommended administered ip
once per 1 or 2 wk. For late maturing individuals, it is ad-
visable to initially prescribe a reduced dose with subsequent
gradual increments.
To date, no evidence of long-term side effects of high doses
of sex steroids have been demonstrated after 8–10 yr. This
limits the need for a prospective trial to assess the effective-
ness of a lower dosage regimen. On the other hand, in view
of a relationship with OC use at a young age and duration
of OC use with increased risks of breast cancer (205), there
is a need for long-term follow-up of individuals treated with
pharmacological doses of estrogens. Similarly, while no hard
evidence of testicular damage has been established after an-
drogen treatment in tall boys, the finding in one study of
marginally elevated FSH levels along with normal sperm
counts, testicular volume, and endocrinological parameters
including inhibin B levels, warrants further study.
In conclusion, it is recommended first to refer constitu-
tionally tall children in the late prepubertal period (8–10 yr)
to secure proper pretreatment evaluation of growth and bone
maturation. Second, to restrict treatment to excessive tallness
or a very outspoken professional desire where height forms
a clear limitation (e.g., pilot, ballet dancer). Third, treatment
should be initiated at an early ’bone age,’ psychosocial con-
straints permitting. Treatment should not start before an age
corresponding to the 10th percentile of the first stage of
pubertal development. Moreover, although retrospective
studies have not provided hard evidence of testicular dam-
age, it should be realized that in boys androgen treatment
might interfere with pubertal testicular development. Fi-
nally, treatment should be continued until complete closure
of the epiphyses has been established radiologically.
In view of the crucial role of GH during the pubertal
growth spurt, it is tempting to speculate on other treatment
modalities that might be as effective or perhaps even more
effective than the current practice. There may be new ways
of effectively suppressing GH secretion not only by soma-
tostatin analogs (223), but also by GHRH or GH antagonists
(224–226).
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